Business Overview: NextCure, Inc. (NASDAQ: NXTC)

---

Executive Summary

NextCure, Inc. is a clinical-stage biopharmaceutical company headquartered in Beltsville, Maryland, founded in 2015 by Dr. Michael Richman (a former MacroGenics executive) to develop treatments for cancer patients whose disease has stopped responding to, or never responded to, existing immunotherapies. The company's technology emerged out of licensed, exclusive worldwide rights to the FIND discovery platform from Yale University.

NextCure's lead program, LNCB74, is an antibody-drug conjugate (ADC) targeting B7-H4, a protein overexpressed in breast, ovarian, and endometrial cancers, developed through a 50/50 cost- and profit-sharing collaboration with LigaChem Biosciences. As a pre-revenue, single-asset clinical-stage company, NextCure's story is almost entirely about whether LNCB74 can differentiate itself in a B7-H4 ADC field that already includes AstraZeneca, BeiGene, GSK, and Mersana.

---

1. Core Business Model & How They Work

NextCure does not yet sell any product — its business model is the standard biotech value-creation cycle, funded by capital markets and partner contributions rather than product sales:

[ Target discovery (FIND platform / Yale license) ] ➡️ [ Antibody/ADC engineering (with LigaChem linker-payload) ] ➡️ [ IND filing & FDA clearance ] ➡️ [ Phase 1 dose escalation/expansion ] ➡️ [ Partner or self-fund later-stage trials ] ➡️ [ Approval & commercialization (not yet reached) ]

Key Operational Drivers

1. FIND Discovery Platform: Licensed exclusively and worldwide from Yale University (since December 2015, amended multiple times through 2022), this platform underpins NextCure's target-identification approach, alongside internal trade secrets and know-how. The license carries low single-digit royalties, minimum annual royalties in the low-to-mid hundreds of thousands of dollars, and up to $2,975,000 in aggregate milestone payments.
2. LigaChem Collaboration: A November 2022 partnership to co-develop up to three ADCs, sharing costs and profits equally. LNCB74 became the first co-development product in April 2023, pairing NextCure's antibody engineering with LigaChem's ConjuAll linker and an MMAE payload (drug-to-antibody ratio of 4) designed for tumor-selective drug release.
3. Clinical Execution: LNCB74's IND was accepted by the FDA in December 2024, with first patient dosed in January 2025; the trial is now in cohort 2 of Phase 1 dose escalation, with backfill cohorts planned for the second half of 2025.
4. Partner-Seeking for Earlier Pipeline: Preclinical/early assets (NC410, NC525, NC181, NC605) are explicitly earmarked for outside partnering or third-party funding rather than internal advancement, conserving NextCure's own cash for LNCB74.

---

2. Business Segments

NextCure operates as a single-segment, pre-revenue clinical-stage biopharmaceutical company — there is no segment reporting, as the entire business is organized around advancing its oncology pipeline.

---

3. Pipeline Portfolio

---

4. Competitive Landscape

NextCure's most direct competitive battleground is the B7-H4 ADC niche, where it faces much larger, better-capitalized rivals:

• AstraZeneca — global oncology leader with a B7-H4 ADC in clinical development and vastly greater commercial and trial infrastructure.
• BeiGene (B7-H4 ADC licensed from DualityBio) — a large, well-funded Chinese-American biotech with broad oncology commercial infrastructure already in place.
• GSK (B7-H4 program licensed from Hansoh) — a major pharma with deep regulatory and commercial resources.
• Mersana — a smaller, ADC-focused biotech competing more directly on technical platform differentiation.

   B7-H4 ADC COMPETITIVE POSITIONING
 ┌──────────────────────────────────────────┐
 │ High                                      │
 │  ▲   [AstraZeneca] [GSK] [BeiGene]         │
 │  │    (Large pharma, deep pockets)          │
 │ CAPITAL                                     │
 │ RESOURCES   [Mersana]                       │
 │  │           (Smaller biotech peer)          │
 │  │   [NEXTCURE]                              │
 │  │    (Single clinical asset, partnered)      │
 │ Low                                          │
 │  └─────────────────────────────────────────►│
 │   Early       CLINICAL STAGE OF ASSET  Later │
 └──────────────────────────────────────────┘

NextCure is the smallest, least-resourced player in this specific niche, making clinical differentiation (tolerability, efficacy, specific tumor types) essential to any eventual partnership or acquisition outcome, since it cannot out-spend its competitors.

---

5. Strategic Strengths & Risks

Strengths

• Risk-shared lead program: the 50/50 cost-sharing LigaChem collaboration on LNCB74 meaningfully reduces NextCure's own cash burden on its most important asset relative to a fully self-funded biotech.
• Platform heritage: the Yale-licensed FIND platform gave NextCure a genuine discovery engine, not just a single licensed-in molecule.
• Disciplined capital allocation: explicitly parking preclinical assets (NC410, NC525, NC181, NC605) for partnering rather than burning cash advancing them internally is a sensible response to a constrained balance sheet.

Risks

• Single clinical asset concentration: with LNCB74 as the only active clinical program, a setback (toxicity, insufficient efficacy signal) would leave the company with almost no near-term clinical value driver.
• Crowded, well-funded competitive field: AstraZeneca, GSK, and BeiGene are all pursuing the same B7-H4 target with vastly more resources, raising real risk that a larger competitor reaches market or generates compelling data first.
• Capital constraints: cash, cash equivalents, and marketable securities fell to $68.6 million at the end of 2024 (from $108.3 million a year earlier), with management guiding runway only into the second half of 2026 — meaning further dilutive financing is likely before LNCB74 could reach a value-inflection readout.
• Paused internal manufacturing: NextCure paused use of its own 2,000-liter cGMP facility in March 2024, adding execution/supply-chain dependency on external manufacturing partners for future clinical material.

---

6. Financial Overview

---

7. Summary Conclusion

NextCure is a classic high-risk, high-reward clinical-stage biotech whose entire near-term value proposition rests on LNCB74, a B7-H4-targeted ADC being co-developed and cost-shared with LigaChem Biosciences in a field that already includes AstraZeneca, GSK, and BeiGene. Its real moat sources, a Yale-licensed discovery platform and a risk-sharing partnership structure, are modest consolation against vastly better-capitalized competitors pursuing the same biological target. The single biggest forward risk is the collision of a shrinking cash runway (into the second half of 2026) with a still-early (cohort 2 of Phase 1) clinical readout timeline, which makes some combination of dilutive financing, a strategic partnership, or an outright sale of the company a near-certainty well before LNCB74 could reach the market on its own.